Koers Cyclacel Pharmaceuticals Inc Nasdaq
Aandelen
US23254L3069
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 3,19 mln. 2,94 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -11 mln. -10,13 mln. | Nettowinst (verlies) 2025 * | -19 mln. -17,51 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,3
x | K/w-verhouding 2025 * |
-0,39
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 76,14% |
Recentste transcriptie over Cyclacel Pharmaceuticals Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 01-08-97 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 01-01-02 |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 17-12-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 83 | 01-03-06 | |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 17-12-20 |
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 01-08-97 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+7,68% | 115 mld. | |
+12,74% | 107 mld. | |
-13,29% | 22,31 mld. | |
-3,99% | 21,6 mld. | |
-6,39% | 18,23 mld. | |
-39,93% | 17,62 mld. | |
+6,86% | 14,26 mld. | |
+32,78% | 12,37 mld. | |
-28,40% | 8,28 mld. |
- Beurs
- Aandelen
- Koers CYCC
- Koers